application of real options valuation to r&d investments in ...

More documents

Recommendations

Info

at:http://content.nejm.org/cgi/content/full/351/21/2147?ijkey=l6S6GwIMoMwGM&keytype=ref&siteid=nejm35. P addock JL , S iegel D R & S m ith JL (1988). ―O ptio n valuation of claim s on realassets: the case of offshore petroleum leases‖. Q uarterly Journal of Economics,103, 479-50836. Paxson, D.A. and Pinto, H. (2003). ―Leader/follower real value functions if themarket share follows a birth/death process‖. In Paxson, D.A. (ed.), Real R&DOptions. Oxford: Butterworth-Heinemann, pp. 208–227.37. Pindyck, R.S. (1993). ―Investments of uncertain cost‖. Journal of FinancialEconomics, 34, 53–76.38. Ross, Stephen A. (1995) Uses, Abuses, and Alternatives to the Net-Present-ValueRule. Financial Management 24, 96-10239. Rogers M.J., Gupta A. and Maranas C.D. (2002), Real Options Based Analysis ofOptimal Pharmaceutical Research and Development Portfolios, AmericanChemical Sociery, 41 (25), pp.6607-6602, retrieved on 31/08/2006, available at:http://pubs.acs.org/cgi-bin/abstract.cgi/iecred/2002/41/i25/abs/ie020385p.html40. Rubinstein, M. (1973), Double Trouble, Risk 5.41. Schwartz, E.S. (2002), Patents and R&D as Real Options, Working Paper, UCLA42. Schwartz, E.S. and Moon, M. (2000a). Evaluating R&D investments. In Brennan,M. and Trigeorgis, L. (eds), Project Flexibility, Agency and Competition. Oxford:Oxford University Press, pp. 85–106.43. Schwartz E.S. and Trigeorgis L. (2001), Real Options and Investment UnderUncertainty: Classical Readings and Recent Contributions, London: MIT Press44. Thomas E. Copeland, J. Fred Weston, Kuldeep Shastri. (2005) Financial theoryand corporate policy (4th ed.), International ed. Pearson Addison Wesley45. Trigeorgis, L. (1993), ―The Nature of Option Interactions and the Valuation ofInvestments with Multiple Real Options‖, The Journal of Financial QuantitativeAnalysis, Vol.28, No.1, March, pg.1-20Page | 74
46. T rigeorgis L . (1995), ―M ethods for E valuating C apital Investm ent D ecisio nsU nder U ncertainty‖. In: R eal O ptions in C apital Investm ent M odel, S trategies,and Applications, Trigeorgis L (Ed) pp31-46, London: Praeger47. Trigeorgis L. (1996), Real Options: Managerial Flexibility and Strategy inResource Allocation. London: The MIT press48. T rigeorgis, L . (2001), ―R eal O ptions: A n O vervie‖, in E . S . S chw artz and L .Trigeorgis (editors), Real Options and Investment under Uncertainty: ClassicalReadings and Recent Contributions, MIT Press:US, pg.103-13449. Trigeorgis, L. (2002), Real Options: Managerial Flexibility and Strategy inResource Allocation, 6 thedition, Asco Trade Typesetting Ltd: Hong Kong,pg.121-17250. Trigeorgis L . S m it H . (2004), ―R eal O ptions and G am es‖, P rinceton U niversityPressWebsite Reference:51. Federal Reserve Statistical Release (2006), Selected Interest Rates, Retrieved on31/08/2006, available at: http://www.federalreserve.gov/releases/h15/data.htm52. Kellogg, D., Charnes, J. M., Demirer, R., (1999). Valuation of a BiotechnologyFirm: An Application of RealOptions Methodologies, Research paper presented atthe 3rd Annual Real Options Conference, June, The Netherlands. Innovation.org,Inside R&D, Retrieved on 31/08/2006, available at:http://www.innovation.org/index.cfm/nonav/Inside_R_&_D#link153. Technopolis (2005), Review of Projects Selected for Funding under the DTITechnology Programme, Technopolis limited, SPRU, available at:http://www.technopolis.co.uk/downloads/571_TP_Final_051115.pdf#search=%22R%26D%20milestone%20can%20be%20considered%20as%20investing%20in%20a%20call%20option%20on%20the%20forthcoming%20milestone%2254. Wierenga D.E and Eaton C.R. (2005), Phases of Product Development, Office ofPage | 75
Page 1 and 2:
APPLICATION OF REAL OPTIONS VALUATI
Page 3 and 4:
Table of ContentsAbstract .........
Page 5 and 6:
List of TablesTable 5.1: Value of O
Page 7 and 8:
Chapter One— IntroductionAs one o
Page 9 and 10:
Then, in Chapter 4, the case study
Page 11 and 12:
and we will have the right to take
Page 13 and 14:
project, to get its salvage value,
Page 15 and 16:
The option to switch:If assets have
Page 17 and 18:
2.2 Advantages of Real Option Valua
Page 19 and 20:
In the case of pharmaceutical R&D,
Page 21 and 22:
delayed in time. Undertaking one pr
Page 23 and 24:
Figure 2.2: Advantages and disadvan
Page 25 and 26:
smallest possible payoff of zero, w
Page 27 and 28:
options applications is the binomia
Page 29 and 30: t: years to expirationr: annual ris
Page 31 and 32: Chapter Three— Apply Real options
Page 33 and 34: on Howell et al (2001).3.1.1 Precli
Page 35 and 36: approved.3.2 real options valuation
Page 37 and 38: Figure 3.3: Comparison of a call op
Page 39 and 40: applying the principals of activity
Page 41 and 42: that has occurred in the past. Depe
Page 43 and 44: Chapter Four— Case StudyFor this
Page 45 and 46: 4.3 DavanrikLAB Pharmaceuticals ori
Page 47 and 48: efficacious for depression only, a
Page 49 and 50: Chapter Five— Case Study Analysis
Page 51 and 52: figure below:Figure 5.3: NPV of Dav
Page 53 and 54: Merck & Co (10%), which gives $2338
Page 55 and 56: approval and other issues. Therefor
Page 57 and 58: of $345m at year 0 (which is $672.3
Page 59 and 60: project turns out to be unprofitabl
Page 61 and 62: these three options, the risk-free
Page 63 and 64: ewrite as, noting all the costs (in
Page 65 and 66: Figure 5.10: Valuation of Option A
Page 67 and 68: Figure 5.12: Valuation of Option A
Page 69 and 70: Figure 5.13 Valuation of Compound r
Page 71 and 72: $ in millionmillion to $113.97 mill
Page 73 and 74: Chapter Six— Limitations and conc
Page 75 and 76: discovery projects, arrives in a di
Page 77 and 78: References1. Amram M & Kulatilaka N
Page 79: 31/08/2006, available at: http://ho
show all

application of real options valuation to r&d investments in ...

Create successful ePaper yourself

Delete template?

Save as template?